<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007621" disease_type="Neoplastic Process" abbrv="">Neoplastic transformation</z:e> requires the elimination of key <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressors, which may result from E3 ligase-mediated proteasomal degradation </plain></SENT>
<SENT sid="1" pm="."><plain>We previously demonstrated a key role for the E3 ubiquitin ligase E6AP in the regulation of promyelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> protein (PML) stability and formation of PML nuclear bodies </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we report the involvement of the E6AP-PML axis in B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> development </plain></SENT>
<SENT sid="3" pm="."><plain>A partial loss of E6AP attenuated Myc-induced B-cell <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>This <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressive action was achieved by the induction of cellular senescence </plain></SENT>
<SENT sid="5" pm="."><plain>B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> deficient for E6AP expressed elevated levels of PML and PML-nuclear bodies with a concomitant increase in markers of cellular senescence, including p21, H3K9me3, and p16 </plain></SENT>
<SENT sid="6" pm="."><plain>Consistently, PML deficiency accelerated the rate of Myc-induced B-cell <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Importantly, E6AP expression was elevated in âˆ¼ 60% of human Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, and down-regulation of E6AP in B-<z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells restored PML expression with a concurrent induction of cellular senescence in these cells </plain></SENT>
<SENT sid="8" pm="."><plain>Our findings demonstrate that E6AP-mediated down-regulation of PML-induced senescence is essential for B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> progression </plain></SENT>
<SENT sid="9" pm="."><plain>This provides a molecular explanation for the down-regulation of PML observed in non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, thereby suggesting a novel therapeutic approach for restoration of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppression in B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
</text></document>